KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to -$517.0 million.

  • Pfizer's Other Non Operating Income fell 11275.72% to -$517.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 billion, marking a year-over-year decrease of 3105.29%. This contributed to the annual value of -$4.4 billion for FY2024, which is 187657.66% down from last year.
  • As of Q3 2025, Pfizer's Other Non Operating Income stood at -$517.0 million, which was down 11275.72% from -$739.0 million recorded in Q2 2025.
  • Pfizer's 5-year Other Non Operating Income high stood at $1.7 billion for Q4 2021, and its period low was -$1.1 billion during Q2 2024.
  • For the 5-year period, Pfizer's Other Non Operating Income averaged around -$92.6 million, with its median value being -$259.0 million (2023).
  • In the last 5 years, Pfizer's Other Non Operating Income skyrocketed by 62842.11% in 2021 and then crashed by 157600.0% in 2024.
  • Pfizer's Other Non Operating Income (Quarter) stood at $1.7 billion in 2021, then tumbled by 96.52% to $59.0 million in 2022, then soared by 169.49% to $159.0 million in 2023, then crashed by 252.83% to -$243.0 million in 2024, then crashed by 112.76% to -$517.0 million in 2025.
  • Its Other Non Operating Income was -$517.0 million in Q3 2025, compared to -$739.0 million in Q2 2025 and -$953.0 million in Q1 2025.